Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 9/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 9/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863518 | 0.88 | GRM1 (0.67) | GRM1PDK4NAMPTGRM5GPR119 | |
| SCHEMBL22441484 | 0.86 | GRM1 (0.48) | GRM1PDK4NAMPTGRM5GPR119 | |
| SCHEMBL21767846 | 0.86 | NAMPT (0.52) | GRM1PDK4NAMPTGRM5GPR119 | |
| SCHEMBL14262836 | 0.86 | PDK4 (0.56) | GRM1PDK4NAMPTGRM5GPR119 | |
| SCHEMBL19459003 | 0.83 | NAMPT (0.50) | GRM1PDK4NAMPTGRM5 | |
| SCHEMBL17002448 | 0.83 | NR1H2 (0.52) | GRM1PDK4NAMPTGRM5 | |
| SCHEMBL3706064 | 0.83 | GRM1 (0.55) | GRM1PDK4NAMPTGRM5MMP13 | |
| SCHEMBL21429656 | 0.83 | GRM1 (0.50) | GRM1PDK4NAMPTGRM5GPR119 | |
| SCHEMBL28471545 | 0.82 | GRM1 (0.46) | GRM1PDK4NAMPTGRM5 | |
| SCHEMBL30545737 | 0.82 | GRM5 (0.43) | GRM1PDK4NAMPTGRM5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658658-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025096637-A1 | SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2025-05-08 | — | — | WO | disclosed |
| CN-119790057-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024162828-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2024-08-08 | — | — | WO | disclosed |
| CN-109996790-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | ABHD6, RABL6, ABHD16A | GRM1 854/4885PDK4 2698/4885NAMPT 2721/4885 |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | GRM1 854/4885PDK4 2698/4885NAMPT 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.